Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups

T. Tomassen1 · M. E. Weidema2 · M. H. S. Hillebrandt-Roeffen2 · C. van der Horst2 · PALGA group* · I. M. E. Desar2 · U. E. Flucke1,3 · Yvonne M. H. Versleijen-Jonkers2

Received: 20 May 2021 / Accepted: 7 December 2021 / Published online: 19 January 2022 © The Author(s) 2022

Abstract

Angiosarcoma (AS) is a rare malignancy with a poor prognosis. It can develop spontaneously or due to previous radiotherapy (RT), ultraviolet (UV) radiation, or lymphoedema (Stewart Treves AS). Novel therapeutic approaches are needed, but progress is hindered because of the heterogeneity and rarity of AS. In order to explore the potential of immune checkpoint inhibition (ICI), we investigated the protein expression of programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1), and CD8+ T cells in 165 AS cases in relation to AS subgroups based on clinical classification and in relation to whole-genome methylation profiling based clusters (A1, A2, B1, B2). High PD-L1 and PD-1 expression were predominantly shown in UV-associated, visceral, and soft tissue AS. RT-associated AS showed predominantly high PD-1 expression. CD8+ T cell infiltration was present in the majority of AS samples. Within the UV-associated AS, two different clusters can be distinguished by DNA methylation profiling. Cases in cluster A1 showed higher PD-1 ($p=0.015$), PD-L1 ($p=0.015$), and CD8+ T cells ($p=0.008$) compared to those in cluster B2, suggesting that these UV-AS tumors are more immunogenic than B2 tumors showing a difference even within one subgroup. In soft tissue AS, combined PD-1 and PD-L1 expression showed a trend toward poor survival ($p=0.051$), whereas in UV-associated AS, PD-1 expression correlated with better survival ($p=0.035$). In conclusion, we show the presence of PD-1, PD-L1, and CD8+ T cells in the majority of AS but reveal differences between and within AS subgroups, providing prognostic information and indicating to be predictive for ICI.

Keywords Angiosarcoma · Subgroups · Programmed cell death 1 · Programmed death-ligand 1 (PD-L1) · Immune checkpoint inhibition

Introduction

AS is a rare and aggressive vasoformative sarcoma arising at different anatomical sites, including skin, soft tissue, bone, and visceral organs. AS can be clinically classified into primary AS (with unknown etiology) or secondary AS, in which DNA damaging factors including radiation, UV light exposure or chronic lymphoedema play an important role [1–3]. Current treatment options include surgery, RT, and/ or chemotherapy, depending on the extent of the disease. In addition, the multi-tyrosine kinase inhibitor pazopanib is also applied in daily practice [4] and treatment with the generic β-blocker propranolol has been suggested [5]. The survival of AS patients is poor with a reported 5-year survival of only 30–40% [6–8], emphasizing the need for novel treatment options.

A potential approach for AS treatment is ICI. Tumor cells can upregulate PD-L1 on their membrane to promote immune suppression. Interaction with the receptor programmed cell death 1 (PD-1) on CD8+ T cells renders the T cell inactive, and thus prevents the killing of tumor cells. ICI with anti-PD-1 antibodies can reactivate the cytotoxic function of T cells leading to the subsequent killing of tumor cells [9].

In order to determine the role of ICI in AS, it is necessary to examine the expression of PD-L1, PD-1, and the presence
of CD8+ T cells as potential biomarkers in this respect. Several studies investigated the expression of these biomarkers in AS, reporting variable levels of expression and varying correlations with prognosis (shown in Table 1). Of note, most studies were performed on cutaneous (predominantly UV-associated) AS or small numbers of other subtypes, often not further specified.

Clinical data with regard to the application of ICI in AS is limited to small case series. In one of these case series, three UV-associated AS were treated with anti-PD-1 (one in combination with CTLA-4 inhibition) showing partial response. One RT-associated AS also showed partial response (with anti-PD1) and one primary breast AS showed progressive disease on axitinib (VEGFR inhibitor) combined with PD-1 inhibition [27]. Four patients suffering from UV-associated AS with significant PD-L1 expression were successfully treated with anti-PD-1 [28–31]. In the recent AS patient-partnered-genomic study of Painter et al., a total of six patients were treated with anti-PD-1 [32]. Of these patients, two out of three UV-associated AS with high mutational burden (>150 mutations/Mb) showed a complete response, whereas no clinical benefit was found in the other three patients (all non-UV AS with low mutational burden) [32]. Pecora et al. published a case of primary AS of the temple and one RT-associated AS with complete clinical remission on combined anti-CTLA4 and anti-PD-1 therapy (Pecora et al. CTOS2019).

Taken together, the previously mentioned studies suggest a potential therapeutic role for ICI in especially UV-associated AS. However, it yet remains unclear whether immunotherapy could be of interest for all AS patients or only for certain pathogenetic subgroups. Our recent DNA methylation profiling study confirmed the existence of these subgroups of AS on an epigenetic level, which did not fully match the clinical subtypes [33].

In the current retrospective study, we aimed to characterize PD-1, PD-L1 expression, and the presence of CD8+ T cells in a large cohort of AS tumor samples and their prognostic relevance to further explore the heterogeneity and the need to differentiate between the different AS subgroups.

Materials and methods

Tumor sample collection

We collected formalin-fixed paraffin-embedded (FFPE) tumor tissue of AS patients by a nationwide search through PALGA (Dutch nationwide network and registry of histology and cytopathology) diagnosed between 1989 and 2015 in the Netherlands [34]. All cases were reviewed by an expert pathologist (UF), and confirmed AS cases were divided into pathogenetic subgroups based on available clinical data and pathology reports [35].

Tumor samples were collected on tissue microarrays (TMAs) and divided into the different subgroups, including 44 UV-associated, 14 cutaneous not UV-associated, 55 RT-associated, 14 Stewart Treves (lymphoedema-associated cases), 27 visceral, and 11 soft tissue cases. Only primary localized tumor samples were selected for this study. Of these samples, 33 have been previously subject to DNA methylation profiling [33].

Clinical data

Clinical data were received from the nationwide Netherlands Cancer Registry and were linked to data from the Dutch pathology registry (PALGA). Ethical approval for the study was obtained from the local certified Medical Ethics Committee of the Radboudumc, Nijmegen, The Netherlands (file number 2016–2686).

Immunohistochemistry

Immunohistochemical analysis was performed to investigate PD-1 and PD-L1 expression and the presence of CD8+ lymphocytes in the tumor. Tonsil (PD-L1+, PD-1+, and CD8+) and appendix (CD8+ and PD1+) served as positive controls. Immunohistochemistry was performed on 4-µm-thick FFPE sections of AS TMAs with one or two cores per sample from representative tumor areas (core size 2 mm) to allow simultaneous examination of patient specimens under identical conditions. Staining was performed in the Lab Vision Autostainer 360 (Thermo Fisher Scientific) by using the EnVision FLEX, pH high Link kit (Dako), and monoclonal rabbit anti-PD-L1 (1:800, clone E1L3N, Cell Signaling Technology), monoclonal mouse anti-PD-1 (1:20, clone MRQ-22, Cell Marque) or monoclonal mouse anti-CD8 (1:80, clone C8/144B, Dako).

PD-L1 expression on the tumor cells was scored as 0% (−), 1–10% (+/−), 10–50% (+) or ≥50% positive tumor cells (++). All CD8 and PD-1 positive T cells were counted and subdivided in three categories: <10 (−), 10–50 (+), or ≥50 positive cells (++) per tumor core [36].

Digital images were generated with VisionTekTM (Sakura, version 2.6) and analyzed at ×20 magnification.

Statistical analysis

Statistical analyses were performed using IBM SPSS Statistics 25. p-values < 0.05 were considered significant and p-values < 0.1 were considered a trend. Relations between categorical parameters were assessed by chi-square or Fisher’s exact testing as appropriate, and associations with overall survival (OS) were assessed by the Kaplan–Meier method.
| Study reference | N   | AS subtype                          | Protein expression | Threshold for positivity | Antibodies                  | Correlation with prognosis |
|-----------------|-----|-------------------------------------|--------------------|--------------------------|-----------------------------|---------------------------|
| Kawamura et al. 2019 [10] | 29  | Cutaneous                           | 12 (41%) PD-1 (%)  22 (76%) PD-L1 (%)  10 (34%) PD-1 and PD-L1 (%) | >5%<sup>2</sup>            | Mouse anti-human ab (CST)  Rabbit anti-human ab (CST) | PD-L1 expression associated with poor survival |
| Gambichler et al. 2020 [11] | 12  | Cutaneous                           | 4 (33%) PD-1 (%)  5 (42%) PD-L1 (%)   |                           | Ab92484 (Abcam)  Ab205921 (Abcam) |                          |
| Fujii et al. 2014 [12] | 55  | Cutaneous (mainly UV)               | 20/40 (50%)        | ≥ Median/HPF             | C8/144B (Dako)                | High number of CD8 in primary tumor correlated with improved survival |
| Honda et al. 2017 [13] | 106 | Cutaneous (mainly UV)               | 19 (18%) PD-1 (%)  32 (30%) PD-L1 (%)  9 (9%) PD-1 and PD-L1 (%) | > 50/3HPF  >5%<sup>2</sup> | NAT105 (Abcam)  SP142 (Spring Biosience) | PD-1 + cells (especially in combination with PD-L1 expression) correlated with improved survival |
| Shimizu et al. 2017 [14] | 52  | Cutaneous (mainly UV)               | 21 (40%) PD-1 (%)  24 (46%) PD-L1 (%)   | ≥5%<sup>2</sup> > Median | Rabbit monoclonal antibody (Abcam)  Abcam | PD-L1 and CD8 are associated with a worse outcome |
| Bagaria et al. 2018 [15] | 26  | Cutaneous (19), other (8)           | 1 (4%)<sup>3</sup> PD-1 (%)  5 (19%)<sup>3</sup> PD-L1 (%) | ≥5%<sup>3</sup>            | NAT105 (Ventana)  SP-142 and SP-263 (Ventana) | No |
### Table 1 (continued)

| Study reference | N  | AS subtype | Protein expression | Threshold for positivity | Antibodies | Correlation with prognosis |
|-----------------|----|------------|--------------------|--------------------------|------------|---------------------------|
|                 |    |            | PD-1 (%)          | PD-L1 (%)                |            |                           |
|                 |    |            | PD-I (%)          | PD-I and PD-L1 (%)       |            |                           |
|                 |    |            | CD8 (%)           | CD8                      |            |                           |
|                 |    |            | CD8 (%)           | CD8                      |            |                           |
| Botti et al.    | 24 | Primary AS (7 breast, 5 soft tissue, 4 bone, 4 skin, 4 visceral) | 16 (66%) | ≥5%2 | SP-142 (Spring Biosience) | No |
| Googe et al.    | 10 | Skin (9), soft tissue (1) | 10 (100%) | Low: ≥1% High: ≥50% | NAT105 (Cell Marque) |  |
| D’Angelo et al. | 3  | n.s        | 0 (0%)            | ≥1%2 ≥5% | 4B11 (Leica Biosystems) |  |
| Kim et al.      | 5  | n.s        | 4 (80%)           | ≥1 | Total score ≥81 |  |
| Vargas et al.   | 17 | n.s        | 5 (29%)           | ≥1%2 |  |  |
| Blessin et al.  | 25 | n.s        | 13 (19%)          | Combined positive score ≥1 | 22C3 (Agilent Technologies) |  |
| Orth et al.     | 6  | n.s        | 2/5 (40%)         | ≥4/HPF ≥1%2 | 315 M (Cell Marque) |  |
| Vargas et al.   | 17 | n.s        | 5 (29%)           | ≥1%2 |  |  |
| Lee et al.      | 70 | n.s        | 13 (19%)          | Combined positive score ≥1 | 22C3 (Agilent Technologies) |  |

Note: N refers to the number of samples. PD-1 and PD-L1 thresholds are given as percentages. Antibodies are listed with their respective vendors. Correlation with prognosis indicates whether the PD-L1 expression is associated with better or worse outcomes.
| Study reference | N | AS subtype | Protein expression | Threshold for positivity | Antibodies | Correlation with prognosis |
|----------------|----|------------|--------------------|--------------------------|------------|-----------------------------|
|                | N | AS subtype | PD-1 (%)           | PD-L1 (%)                | PD-1 ( %)  | PD-L1 ( %)                  | CD8 (%)         | CD8 threshold |              |
|                |    |            | PD-1 expression (%)| PD-L1 expression (%)    | PD-1 and PD-L1 expression (%) | CD8 expression (%) |                |              |
|                |    |            | PD-1 threshold     | PD-L1 threshold         | CD8 threshold |                            |                |              |
| 286 Cutaneous  | 44/156 | (28%) | 92/212 (43%) | 28/144 (19%) | 53/101 (52%) | >50/3HPF | ≥1% to ≥5% | ≥Median |
| 7 Breast       | 4/7 | (57%) | 5/6 (83%) | 1/1 (100%) | 1/1 (100%) | ≥1% to ≥5% | ≥5% |
| 6 Soft tissue  | 1/1 (100%) | 5/6 (83%) | 1/1 (100%) | 1/1 (100%) | | | ≥5% |
| 4 Bone         | 4/4 (100%) | 5/11 (45%) | 1/3 (33%) | | | ≥1 to ≥4/HPF | ≥1% to ≥8 | ≥5% |
| 169 n.s        | 6/10 (60%) | 35/136 (26%) | 5/11 (45%) | 1/3 (33%) | | | |

Abbreviations: AS, angiosarcoma; CST, Cell Signaling Technology, HPF, high power field; n.s., not specified; SCB, Santa Cruz Biotechnology; UV, UV-associated AS;

1For PD-L1, the staining intensity score was classified as 0 (no staining), 1 (weak staining), and 2 (intermediate staining), and 3 (strong staining). The area of staining was scored as 0 (0–10% of the cells stained), 1 (11–33% of the cells stained), 2 (34–66% of the cells stained), and 3 (67–100% of the cells stained). The total score was determined as the sum of the intensity score and the staining proportion score of two different TMAs. The total score ≥ 8 was determined as positive. 2Membranous expression of tumor cells. 3Expression not displayed per subtype. 4Results are summarized per subtype.
with the logrank test. Tumors positive for one marker or a combination of markers were compared to tumors negative for that particular marker or combination. A distinction between the different levels of expression was made in the analysis.

### Results

#### Immune profiles in AS subtypes

The expression of PD-1, PD-L1, and CD8 was assessed in 165 AS samples divided over 6 different subgroups. Patient characteristics are shown in Table 2. Staining results are presented in Table 3 with an example of each staining shown in Supplementary Fig. 1.

High PD-1 and PD-L1 expressions were predominantly seen in clinically defined soft tissue (40%), UV-associated (18%), and visceral (17%) AS subgroups. Besides, RT-associated AS showed predominantly high PD-1 expression (32%). Infiltration of high numbers of CD8+ T cells was present in the majority of AS samples across all different subgroups (64–86%) (Table 3).

The two main clusters (A and B) defined by our previous genome-wide array-based DNA methylation profiling study were each subdivided into 2 separate clusters (A1, A2 and B1, B2) (Fig. 1A). Cluster A1 consisted exclusively of UV-associated cases, whereas A2 primarily consisted of RT-associated cases. Cluster B1 had both visceral and soft tissue cases, and cluster B2 was mixed, including cases of UV-associated AS.

In the current study, a significantly higher PD-L1 expression (≥10%) and PD-1 expression (≥10) was found in the UV-associated cases in cluster A1 versus those in cluster B2 (for both stainings 6/7 (86%) in A1 versus 0/4 (0%) in B2, p = 0.015) (Fig. 1B).

A high amount of CD8-positive T cells (≥50) was observed in all UV-associated cases in cluster A1 versus none of the UV-associated cases in cluster B2 (for both stainings 7/7 (100%) in A1 versus 0/3 (0%) in B2 (1 case was not evaluable), p = 0.008) (Fig. 1B). A difference in the number of copy number variations (CNVs) was seen between the UV-associated AS cases in cluster A1 versus B2, as already described.
Fig. 1 Overview of the division of AS subgroups over the different methylation clusters (A). Expression of PD-1, PD-L1, CD8, and the presence of copy number variations (CNVs) in UV-associated AS in cluster A1 versus B2 (B).
in our methylation profiling study (mean number of CNVs 34.4 (range 23–39) in cluster A1 versus 7.3 (range 3–17) in cluster B2, \( p < 0.001 \) (Fig. 1B).

For the other AS subgroups, no significant differences in expression of PD-L1, PD-1, or CD8 were observed between clusters (Supplementary Fig. 2).

### Prognostic relevance of the immune profile

In Supplementary Table 1, we present the univariate analysis of associations of the expression of the different markers with overall survival. In the total group PD-1, PD-L1, CD8, or combined expression did not significantly correlate with survival, although we did observe a trend toward a worse overall survival for patients with \( \geq 10\% \) PD-L1 expression in their tumor versus \( < 10\% \) PD-L1 (median 11.0 \( \pm \) 2.4 versus 17.1 \( \pm \) 4.1 months, respectively, \( p = 0.088 \)) and for patients with both \( \geq 10\% \) PD-L1 expression and \( \geq 10\% \) CD8-positive T cells in their tumor versus those with no expression of both markers (median 11.0 \( \pm \) 2.4 months versus 18.4 \( \pm \) 4.1 months, respectively, \( p = 0.083 \)) (Fig. 2A).

In the cutaneous not UV-associated, RT-associated, Stewart Treves, and visceral AS groups, no significant correlations with survival were observed. We excluded correlations when groups of only one patient were involved.

In patients with soft tissue AS, the presence of both PD-1 (\( \geq 10 \)) and PD-L1 (\( \geq 10 \)) showed a trend toward poor survival (estimate mean survival time 6.8 \( \pm \) 2.7 months (both positive, \( n = 6 \)) versus 145.5 \( \pm \) 41.3 months (not both positive, \( n = 4 \)), \( p = 0.051 \)) (Fig. 2B).

In UV-associated AS, the presence of PD-1 positive cells in the tumor (\( \geq 10 \)) correlated with better overall survival (median 20.6 \( \pm \) 8.5 months for PD1 \( \geq 10 \) versus 5.8 \( \pm \) 2.1 months for PD1 < 10, \( p = 0.035 \)). The same applies to the presence of high numbers of PD-1 positive cells in the tumor (\( \geq 50 \)) (median 22.1 \( \pm \) 16.7 months for PD1 \( \geq 50 \) versus 8.3 \( \pm \) 2.8 months for PD1 < 50, \( p = 0.020 \)) (Fig. 2C). All PD-1 positive tumors in this subgroup were also CD8 positive.

UV-associated AS patients in cluster A1 (instable, more immunogenic (“hot”) cluster, \( n = 7 \)) showed a trend toward better overall survival compared to those in cluster B2 (stable, “cold” cluster, \( n = 4 \)) (median 22.2 \( \pm \) 11.4 versus 1.6 \( \pm \) 4.5 months, \( p = 0.053 \)) (Fig. 2D).

### Correlations with patient characteristics

Correlations with gender, age, tumor depth, and presence of distant metastases are presented in Table 4. In the total group, PD-L1 expression (\( \geq 10\% \)) already showed a trend toward a correlation with the male gender (\( p = 0.075 \)), whereas high PD-L1 expression (\( \geq 50\% \)) correlated significantly with the male gender (17/47 (36\%) male versus 19/98 (19\%) female, \( p = 0.039 \)). Also, combined positive PD-L1 and CD8 (\( \geq 10\% \)) expression and high PD-L1 and CD8 (\( \geq 50\% \)) expression showed a trend toward a correlation with the male gender (\( p = 0.070/0.075 \)). High PD-L1 expression (\( \geq 50\% \)) was also more common in deep tumors (3/4 (75\%) deep versus 6/40 (15\%) superficial tumors, \( p = 0.023 \)).

In RT-associated AS, PD-L1 expression (\( \geq 1 \)) showed a trend toward a correlation with the absence of metastases (\( p = 0.066 \)), whereas no significant correlation with the presence of distant metastases was observed at the thresholds of 10 or 50\%. High PD-L1 expression (\( \geq 50\% \)) did show a significant correlation with the age below 70 years (4/21 (19\%) < 70 years of age versus 0/27 (0%) \( \geq 70 \) years of age, \( p = 0.031 \)). All cases with high PD-L1 expression also showed a high CD8 expression. The combination of both high PD-L1 and PD-1 expressions, as well as the combination of high PD-L1, PD-1, and CD8 expressions showed a trend toward a correlation with the age below 70 years (\( p = 0.077 \)). High PD-L1 expression (\( \geq 50 \)) correlated with the presence of distant metastases (PD-1 \( \geq 50 \) in 3/3 (100\%) patients with distant metastases versus 11/27 (41\%) without distant metastases, \( p = 0.034 \)). Cases with high PD-1 expression also showed high CD8 expression.

In visceral AS, high PD-L1 expression (\( \geq 50\% \)) correlated with the absence of distant metastases (PD-L1 \( \geq 50 \) in 0/5 (0\%) patients with distant metastases versus 8/13 (62\%) without distant metastases, \( p = 0.036 \)).

### Discussion

This is the first study mapping the immunological landscape in different AS subgroups as well as in genome-wide methylation profiling clusters. We detected relevant differences between the various subgroups.

We showed a high expression of both PD-1 and PD-L1 predominantly in UV-associated, visceral, and soft tissue AS subgroups and high PD-1 expression in RT-associated AS, whereas infiltration of CD8 + T cells was present in the majority of AS samples. In soft tissue AS the presence of both PD-1 and PD-L1 expression showed a trend toward poor survival, whereas in UV-associated AS, PD-1 expression was correlated with better survival.

These results reflect the heterogeneity in immunological response associated with prognosis for the diverse AS subgroups and underline the need to differentiate between them. So far, most studies have analyzed PD-1, PD-L1, and CD8 expression only in cutaneous, mainly UV-associated AS (displayed in Table 1). Based on the observed high expression of PD-1, PD-L1, and CD8 in visceral and soft tissue AS in the current study, ICI might also be successful in these subgroups. Individual immune profiling before the start of ICI could be considered to select more vulnerable tumors.
Fig. 2 Kaplan–Meier curves showing the significant differences and trends in overall survival in A AS total group, B soft tissue AS, and C UV-associated AS according to PD-1, PD-L1 expression, or the presence of CD8+ T cells in the tumor and a Kaplan–Meier curve showing the difference in overall survival between UV-associated AS in cluster A1 versus B2 (D).
In UV-associated AS, some studies reveal a correlation between PD-L1 positivity and worse prognosis and/or tumor cell proliferation [10, 14]. Honda et al. found an association between high infiltration of PD-1 positive cells and favorable survival [13]. This is in accordance with our results. One explanation could be that PD-1 expression might reflect antitumor immune response instead of tumor evasion. This indicates a response of the tumor cell to high immune pressure by CD8+ T cells and could lead to a better prognosis as long as the balance is on the side of antitumor immunity [37, 38].

Our finding that UV-associated AS may be classified in “cold” (low number of CD8 + T cells (< 50) and low or no PD-1 / PD-L1 expression (< 10(%) ) and “hot” AS (high number of CD8 + T cells (≥ 50) and high PD-1/ PD-L1 expression (≥ 10(%) )) according to their methylation profile reflects with the data of Chan et al. who also showed immunologically “cold” and “hot” clusters within the UV-associated and other cutaneous AS of the head and neck (n = 13) based on NanoString profiling [39]. The “hot” tumors are expected to benefit from ICI; however, to draw definitive conclusions, a thorough investigation is necessary.

Recent studies have however shown that expression levels of PD-1, PD-L1, and CD8 on their own might not be sufficient to predict response to ICI [40, 41]. Other factors that may be important are tumor mutational burden (TMB), inflammation, and the further composition of the tumor immune microenvironment [42, 43]. It will be of (therapeutic) interest whether these markers also play a role in angiosarcomas.

### Table 4 Correlations between (combinations of) biomarkers and clinical data

| AS subgroup | Clinical marker | PD-L1 1 | PD-L1 10 | PD-L1 50 | PD-1 10 | PD-1 50 | PD-L1 and PD-1 10 | PD-L1 and PD-1 50 | PD-L1 and CD8 10 | PD-L1 and CD8 50 | PD-1 and CD8 10 | PD-1 and CD8 50 | PD-L1 and PD-1 and CD8 10 | PD-L1 and PD-1 and CD8 50 |
|-------------|----------------|---------|---------|---------|---------|---------|------------------|------------------|-----------------|-----------------|----------------|----------------|-------------------------------|-------------------------------|
| All         | Gender         | -       | 0.075   | 0.039   | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Age            | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Tumor depth    | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Distant metastases | -   | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
| UV associated | Gender      | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Age            | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Tumor depth    | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Distant metastases | -   | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
| Cutaneous not UV | Gender  | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Age            | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Tumor depth    | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Distant metastases | 0.066 | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
| RT associated | Gender      | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Age            | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Tumor depth    | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Distant metastases | 0.034 | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
| Stewart Treves | Gender      | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Age            | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Tumor depth    | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Distant metastases | 0.036 | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
| Visceral     | Gender         | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Age            | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Tumor depth    | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Distant metastases | -   | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
| Soft tissue  | Gender         | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Age            | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Tumor depth    | -       | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |
|             | Distant metastases | -   | -       | -       | -       | -       | -                | -                | -               | -               | -               | -               | -                               | -                               |

p-value < 0.05 is considered significant (p-value shown in bold), p-value < 0.1 is considered a trend (p-value shown); — means no significant correlation. Tumor depth compares deep and superficial tumors, age compares patients < 70 years of age with patients ≥ 70 years of age.
In the study of Chan et al., cases with high TMB \((n = 3)\) were all present in the immune “hot” cluster \([39]\). According to our copy number variation data in our previous methylation study, the immune “hot” UV-associated cluster appears to be the population harboring chromosomal instability \([33]\). Similar to tumor mutational burden, chromosomal instability might also reflect the neoantigen load of the tumor that mediates T cell responses against the tumor \([44]\).

A very recent study suggests the use of tumor DNA methylation profiles to predict the response to anti-PD1 inhibitors in sarcomas \([40]\). They included only 2 AS patients (1 breast, 1 chest wall) who did not respond to the anti-PD1 treatment. Although we do not know if the patients in our study respond to ICI, we do see a difference in methylation profiles within the UV-associated AS which corresponds to different immune profiles.

In order to generate a more robust way to predict the response to ICI, it is necessary to analyze and combine multiple biomarkers and validate those in a large clinical trial.

It is remarkable that all previous studies chose a cutoff value of \(\geq 1\%\) or \(\geq 5\%\) for PD-L1 positive staining. Unlike the other studies, we performed statistical analyses on PD-L1 using different cutoff values (\(\geq 1\%, \geq 10\%,\) and \(\geq 50\%\)). We found no statistically relevant correlations using a cutoff value of \(\geq 1\%\). This may suggest that in angiosarcomas, PD-L1 as a prognostic marker is more valuable using a cutoff value of \(\geq 10\%\) or \(\geq 50\%\) compared to \(\geq 1\%\). The optimal cutoff value for PD-L1 is still unknown and seems to be tumor-specific and even antibody-specific \([45–47]\). Therefore, the optimal PD-L1 cutoff value still needs to be evaluated. Furthermore, in epithelial cancer, different scores are established for PD-L1, including tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate \([48]\). In this paper, we only determined TPS. The right scoring system for AS is not yet established. Although it would make sense to add the PD-L1 positive immune cells instead of focusing only on the tumor cells, we also feel that manual counting on a stained slide without other markers to distinguish the type of immune cells is not enough. It would make sense to determine these scores in a future study by using multiplex immunostaining and quantifying different types of immune cells and their PD-L1 expression in a large collection of angiosarcomas.

In conclusion, with this retrospective immunohistochemical study, we present evidence of subgroup-associated immune profiles of AS corresponding to pathogenesis, prognosis, and epigenetic mechanisms. We showed that expression of the immunological markers PD-1 and PD-L1 was clearly present in several AS subgroups besides cutaneous (UV-associated) AS, with varying prognostic correlations. We confirmed the existence of two different clusters within the UV-associated subgroup, revealing one immunologically “hot” (chromosomally unstable) and one “cold” (chromosomally stable) cluster. Given the scarce treatment options in AS, our results provide a rationale for the future investigation/application of immune checkpoint inhibition in AS.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1007/s12026-021-09259-4.

Author contribution All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by Tess Tomassen, Melissa Hillebrandt-Roeffen, Uta Flucke, and Yvonne Versleijen-Jonkers. The first draft of the manuscript was written by Tess Tomassen, and all authors commented on the manuscript. All authors read and approved the final manuscript.

Funding This research was funded by the “Stichting Bergh in het Zadel voor de kankerbestrijding” (NL).

Data availability Data and material are available upon request.

Code availability Not applicable.

Declarations

Ethics approval Ethical approval for the study was obtained from the local certified Medical Ethics Committee of the Radboudumc, Nijmegen, The Netherlands (file number 2016–2686).

Consent to participate Not applicable.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cao J, Wang J, He C, Fang M. Angiosarcoma: a review of diagnosis and current treatment. Am J Cancer Res. 2019;9;2303–13.
2. Florou V, Wilky BA. Current and Future Directions for Angiosarcoma Therapy. Curr Treat Options Oncol. 2018;19;14.
3. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11:983–91.
4. Kollmar A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litiere S, Marreaud S, Gronchi A, Kasper B, Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol. 2017;56:88–92.
15. PD-L1 expression in the soft tissue sarcoma microenvironment. G. Kuk D, Tap WD. Prevalence of tumor-infiltrating lymphocytes and Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Olson JE. Immune checkpoint markers in superficial angiosarcoma. Int J Cancer. 2014;134:2393–402.

16. Improvement of long-term outcomes for patients with extra-abdominal soft tissue sarcoma regionalization to high-volume centers, improved compliance with guidelines or both? Sarcoma. 2018;2018:8141056.

17. Botti G, Scognamiglio G, Marra L, Pizzolorusso A, Bi Donito M, De Cecio R, Cantile M, De Chiara A. Programmed death ligand 1 (PD-L1) expression in primary angiosarcoma. J Cancer. 2017;8:3166–72.

18. Googe PB, Flores K, Jenkins F, Merritt B, Moschos SJ, Grilley-olson JE. Immune checkpoint markers in superficial angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and tumor-infiltrating lymphocytes. Am J Dermatopathol. 2020.

19. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, Kang MJ, Jang KY. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e28870.

20. Boxberg M, Steiger K, Lenze U, Rechil H, von Eisenhart-Rothe R, Wörtler K, Weichert W, Langer R, Specht K. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy. Oncoimmunology. 2018;7:e1389366.

21. Rosemehmetoglu K, Ozogul E, Babaoğlu B, Tezel GG, Gedikoglu G. Programmed death ligand 1 (PD-L1) expression in malignant mesenchymal tumors. Turk Patoloji Derg. 2017;1:192–7.

22. Que Y, Xiao W, Pan YX, Liang Y, Yan SM, Chen HY, Li QQ, Xu BS, Zhou ZW, Zhang X. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer. 2017;8:2018–25.

23. Blessin NC, Spriestersbach P, Li W, Mandelkow T, Dum S, Simon R, Hube-Magg C, Lutz F, Viehweger F, Lenhardt M, Fraune C, Nickelsen V, Fehrle W, Golbel C, Weidemann S, Clauditz T, Lebok P, Moller K, Steurer S, Izbicki JR, Sauter G, Minner S, Jacobsen F, Luebeck EM, Buscheck F, Hoffmayer D, Wilczak W, Burandt E, Hinsch A. Prevalence of CD8(+) cytotoxic lymphocytes in human neoplasms. Cell Oncol (Dordr). 2020;43:421–30.

24. Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Perez L, Wehbeck FS, Lindner L, Issels R, Kirchner T, Anderl-Holm A, Grunewald TGP, Knosel T. Comparison of the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunol Immunother. 2020;69:1353–62.

25. Vargas AC, Maclean FM, Sioson L, Tran D, Bonar F, Mahar A, Cheah AL, Russell P, Grimison P, Richardson L, Gill AJ. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLoS One. 2020;15:e0222551.

26. Lee JB, Ahn BC, Kim SH, Lee YH, Han JW, Jeon MK, Kim SH, Kim HS. Prognostic implications of PD-L1 expression in patients with angiosarcoma. Future Sci OA. 2021;7(5):FSO691.

27. Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019;7:213.

28. Sindhu S, Gimmer LH, Cramer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017;5:58.

29. Xu F, Zheng J, Fu M, Zhou H. Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case report. Immunotherapy. 2020;12:771–6.

30. Hamacher R, Kampfe D, Reuter-Jessen K, Pottgen C, Podleska LE, Farzaliyev F, Steinau HU, Schuler M, Schildhaus HU, Bauer S. Dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab. Jco Precis Oncol. 2018;2:1–7.

31. Momen S, Fassihi H, Davies HR, Nikolaou C, Degasperi A, Stefanato CM, Dias JML, Dassalgut D, Craythorne E, Sarkany R, Papa S, Nik-Zainal S. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Csh Mol Case Stud. 2019:5.

32. Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gomez Tejeda Zanudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, Van Tine BA, Lander ES, Golub TR, Wagle N. The Angiosarcoma...
Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020;26:181–7.

33. Weidema ME, van de Geer E, Koelsche C, Desar IME, Kemmeren P, Hillebrandt-Roeffen MHS, Ho VKY, van der Graaf WTA, Versleijen-Jonkers YMH, von Deimling A, Flucke UE, PGroup. DNA methylation profiling identifies distinct clusters in angiosarcomas. Clin Cancer Res. 2020;26(93):100.

34. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29:19–24.

35. Weidema ME, Flucke UE, van der Graaf WTA, Ho VKY, Hillebrandt-Roeffen MHS, Dutch Nationwide N, Registry of H, Cytopathology G, Versleijen-Jonkers YMH, Husson O, Desar IME. Prognostic Factors in a Large nationwide cohort of histologically confirmed primary and secondary angiosarcomas. Cancers (Basel). 2019;11.

36. van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent. Oncotarget. 2017;8:71371–84.

37. Cooper WA, Tran VC, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O’Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung cancer (Amsterdam, Netherlands). 2015;89:181–8.

38. Schalper KA, Velchetti V, Carvajal D, Wimerth B, Brown J, Puszta L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773–82.

39. Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, Tay TKY, Selvarajan S, Md Nasir ND, Loh JH, Ong CK, Huang D, Tan J, Li Z, Ng CC, Tan TT, Masuzawa M, Sung KW, Farid M, Quek RHH, Tan NC, Teo MCC, Rozen SG, Tan P, Futreal A, Teh BT, Soo KC. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Invest. 2020;130(11):5833–46.

40. Starzer AM, Berghoff AS, Hamacher R, Tomasich E, Feldmann K, Hatziiioannou T, Traint S, Lamm W, Noebauer-Huhmann IM, Furtner J, Mullauer L, Amann G, Bauer S, Schildhaus HU, Preusser M, Heller G, Brodowicz T. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. J Immunother Cancer. 2021;9.

41. Petitpierre F, Meylan M, de Reyneys A, Sautes-Fridman C, Fridman WH. The Tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784.

42. Meyers DE, Banerji S. Biomarkers of immune checkpoint inhibitor efficacy in cancer. Curr Oncol. 2020;27:S106–14.

43. Petitpierre F, de Reyneys A, Keung EZ, Chen TW, Sun CM, Calde-raro J, Jeng YM, Hsiao LP, Lacroix L, Bougouin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laiyet YH, Toumoulle M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautes-Fridman C, Tawbi HA, Fridman WH. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556–60.

44. Li J, Wei Q, Wu X, Sima J, Xu Q, Wu M, Wang F, Mou H, Hu H, Zhao J, Li D, Hu J, Zhang L, Zhu X, Chen L, Luo C, Yan J, He J, Ma Y, Shao Y, Wu W, Ying J. Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. Clin Transl Med. 2020;10:e118.

45. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhauff M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dornage C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:3627–39.

46. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Luncford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med. 2015;372:378–2018–28.

47. Zajac M, Ye J, Mukhopadhyay P, Jin X, Ben Y, Antal J, Gupta AK, Rebelatto MC, Williams JA, Walker J. Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS One. 2020;15:e0231936.

48. Schildhaus HU. Predictive value of PD-L1 diagnostics. Pathololgy. 2018;39:498–519.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.